JP6498212B2 - Ｃｄｋ阻害剤としてのピラゾロ［１，５‐ａ］ピリミジン‐５，７‐ジアミン化合物及びその治療用途 - Google Patents

Ｃｄｋ阻害剤としてのピラゾロ［１，５‐ａ］ピリミジン‐５，７‐ジアミン化合物及びその治療用途 Download PDF

Info

Publication number
JP6498212B2
JP6498212B2 JP2016553387A JP2016553387A JP6498212B2 JP 6498212 B2 JP6498212 B2 JP 6498212B2 JP 2016553387 A JP2016553387 A JP 2016553387A JP 2016553387 A JP2016553387 A JP 2016553387A JP 6498212 B2 JP6498212 B2 JP 6498212B2
Authority
JP
Japan
Prior art keywords
independently
alkyl
compound according
compound
saturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016553387A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506250A5 (enExample
JP2017506250A (ja
Inventor
ボンドケ，アレクサンダー
クロル，セバスティアン
バレット，アンソニー
フヒター，マシュー
スラファー，ブライアン
アリ，シマック
クームズ，チャールズ
パトリック スナイダー，ジェームズ
パトリック スナイダー，ジェームズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd, Cancer Research Technology Ltd filed Critical Imperial Innovations Ltd
Publication of JP2017506250A publication Critical patent/JP2017506250A/ja
Publication of JP2017506250A5 publication Critical patent/JP2017506250A5/ja
Application granted granted Critical
Publication of JP6498212B2 publication Critical patent/JP6498212B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016553387A 2014-02-21 2015-02-20 Ｃｄｋ阻害剤としてのピラゾロ［１，５‐ａ］ピリミジン‐５，７‐ジアミン化合物及びその治療用途 Active JP6498212B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201403093A GB201403093D0 (en) 2014-02-21 2014-02-21 Therapeutic compounds and their use
GB1403093.6 2014-02-21
PCT/GB2015/050494 WO2015124941A1 (en) 2014-02-21 2015-02-20 Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use

Publications (3)

Publication Number Publication Date
JP2017506250A JP2017506250A (ja) 2017-03-02
JP2017506250A5 JP2017506250A5 (enExample) 2018-03-08
JP6498212B2 true JP6498212B2 (ja) 2019-04-10

Family

ID=50482596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553387A Active JP6498212B2 (ja) 2014-02-21 2015-02-20 Ｃｄｋ阻害剤としてのピラゾロ［１，５‐ａ］ピリミジン‐５，７‐ジアミン化合物及びその治療用途

Country Status (23)

Country Link
US (4) US9932344B2 (enExample)
EP (1) EP3107914B8 (enExample)
JP (1) JP6498212B2 (enExample)
CN (1) CN106103445B (enExample)
AU (1) AU2015220560B2 (enExample)
BR (1) BR112016018633B1 (enExample)
CA (1) CA2939786C (enExample)
CY (1) CY1121588T1 (enExample)
DK (1) DK3107914T3 (enExample)
ES (1) ES2721268T3 (enExample)
GB (1) GB201403093D0 (enExample)
HR (1) HRP20190685T1 (enExample)
HU (1) HUE043122T2 (enExample)
LT (1) LT3107914T (enExample)
ME (1) ME03427B (enExample)
NZ (1) NZ724323A (enExample)
PL (1) PL3107914T3 (enExample)
PT (1) PT3107914T (enExample)
RS (1) RS58704B1 (enExample)
SI (1) SI3107914T1 (enExample)
SM (1) SMT201900266T1 (enExample)
TR (1) TR201905647T4 (enExample)
WO (1) WO2015124941A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
US10131679B2 (en) 2014-10-31 2018-11-20 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole compound
CN107207488B (zh) 2014-12-17 2020-11-17 伦敦皇家学院 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物
US10913744B2 (en) * 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
AU2016281225B2 (en) 2015-06-15 2020-10-15 Ube Corporation Substituted dihydropyrrolopyrazole derivative
WO2017096326A1 (en) 2015-12-02 2017-06-08 Massachusetts Institute Of Technology Method for efficient generation of neurons from non-neuronal cells
UA125852C2 (uk) 2016-08-31 2022-06-22 Ле Лаборатуар Сервьє Інгібітори клітинних метаболічних процесів
IL317854A (en) 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
WO2019035866A1 (en) * 2017-08-15 2019-02-21 The Brigham & Women's Hospital, Inc. COMPOSITIONS AND METHODS FOR TREATING THE TUBEROUS SCLEROSIS COMPLEX
GB201715194D0 (en) * 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
TWI703149B (zh) * 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
MY207194A (en) * 2018-04-11 2025-02-05 Qurient Co Ltd Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives
KR102966455B1 (ko) * 2018-04-11 2026-05-15 주식회사 큐리언트 사이클린 의존성 키나아제의 선택적 억제제로서의 피라졸로-트리아진 및/또는 피라졸로피리미딘 유도체
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
SG11202013175SA (en) 2018-06-29 2021-01-28 Kinnate Biopharma Inc Inhibitors of cyclin-dependent kinases
KR20250174699A (ko) * 2018-10-30 2025-12-12 크로노스 바이오, 인코포레이티드 Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법
JP7530297B2 (ja) 2018-11-14 2024-08-07 Ｕｂｅ株式会社 ジヒドロピロロピラゾール誘導体
CN109860354B (zh) * 2018-12-28 2020-05-19 南京邮电大学 同质集成红外光子芯片及其制备方法
US20220144841A1 (en) * 2019-03-13 2022-05-12 The Translational Genomics Research Institute Trisubstituted pyrazolo [1,5-a] pyrimidine compounds as cdk7 inhibitors
CN114269742B (zh) * 2019-07-10 2024-07-16 常州千红生化制药股份有限公司 作为治疗剂的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶基)嘧啶-2-胺的衍生物
CN114901284A (zh) * 2019-10-29 2022-08-12 希洛斯医药品股份有限公司 用细胞周期蛋白依赖性激酶7(cdk7)抑制剂治疗生物标志物鉴定的患者的癌症的方法
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
CA3174507A1 (en) * 2020-03-06 2021-09-10 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of cdk12
US20230158159A1 (en) * 2020-04-24 2023-05-25 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
AU2022211514B2 (en) * 2021-01-22 2024-06-13 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Substituted pyrazolo[1,5-a]pyrimidine-7-amine derivative, and compositions and medical use thereof
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
WO2023001061A1 (en) * 2021-07-17 2023-01-26 Jingrui Biopharma Co., Ltd. Cdk7 selective inhibitors as anticancer agents
EP4436569A4 (en) * 2021-11-24 2025-10-01 Kronos Bio Inc POLYMORPHIC AND SALT FORMS OF (LS,3S))-N-(5-(PENTAN-3-YL)PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)CYCLOPENTANE-L,3-DIAMINE
CA3251059A1 (en) 2022-05-02 2023-11-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions, systems and methods for modulating a target gene
US20260191864A1 (en) * 2022-11-10 2026-07-09 Emory University Uses of Hydroimidazopyridopyrimidinone Derivatives for Managing Aneurysms or Other Vascular Conditions or Diseases
CN120752238A (zh) * 2023-02-20 2025-10-03 江苏正大丰海制药有限公司 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用
CN120712267A (zh) * 2023-02-21 2025-09-26 杭州德睿智药科技有限公司 作为CDKs抑制剂的新型并杂环类新化合物及其应用
WO2025006569A1 (en) 2023-06-27 2025-01-02 Arvinas Operations, Inc. Combinations of estrogen receptor degraders and cdk7 inhibitors for the treatment of cancer
EP4777509A1 (en) 2023-09-11 2026-07-22 Assia Chemical Industries Ltd. Solid state forms of samuraciclib
WO2025208104A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof
WO2025208097A1 (en) * 2024-03-29 2025-10-02 The Translational Genomics Research Institute Cdk7 inhibitors and methods of use thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers
WO2026057043A1 (zh) * 2024-09-14 2026-03-19 正大天晴药业集团股份有限公司 作为cdk抑制剂的三并环化合物及其应用
EP4717312A1 (en) * 2024-09-27 2026-04-01 Perha Pharmaceuticals Pyrazolo[1,5-a]pyrimidine derivatives useful as a medicament

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
JP4881558B2 (ja) 2002-09-04 2012-02-22 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP2006516573A (ja) 2003-01-31 2006-07-06 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
JP4564485B2 (ja) 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
JP2010529140A (ja) * 2007-06-05 2010-08-26 エモリー・ユニバーシテイ サイクリン依存性キナーゼの選択的阻害剤
PL2509602T3 (pl) 2009-12-04 2017-08-31 Senhwa Biosciences, Inc. Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
DK2734205T3 (en) * 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use

Also Published As

Publication number Publication date
CA2939786A1 (en) 2015-08-27
CY1121588T1 (el) 2020-05-29
US20180273540A1 (en) 2018-09-27
ES2721268T3 (es) 2019-07-30
EP3107914A1 (en) 2016-12-28
WO2015124941A1 (en) 2015-08-27
HUE043122T2 (hu) 2019-08-28
US20200055862A1 (en) 2020-02-20
US20210253583A1 (en) 2021-08-19
EP3107914B1 (en) 2019-01-30
AU2015220560B2 (en) 2019-05-16
US10414772B2 (en) 2019-09-17
LT3107914T (lt) 2019-05-27
PT3107914T (pt) 2019-05-20
AU2015220560A1 (en) 2016-10-06
BR112016018633A2 (enExample) 2017-08-08
US10927119B2 (en) 2021-02-23
GB201403093D0 (en) 2014-04-09
SMT201900266T1 (it) 2019-07-11
DK3107914T3 (en) 2019-04-29
BR112016018633B1 (pt) 2022-08-30
JP2017506250A (ja) 2017-03-02
SI3107914T1 (sl) 2019-05-31
US11566029B2 (en) 2023-01-31
HRP20190685T1 (hr) 2019-06-14
PL3107914T3 (pl) 2019-09-30
CN106103445B (zh) 2019-08-09
RS58704B1 (sr) 2019-06-28
NZ724323A (en) 2022-02-25
CN106103445A (zh) 2016-11-09
EP3107914B8 (en) 2019-07-17
TR201905647T4 (tr) 2019-05-21
CA2939786C (en) 2022-03-08
ME03427B (me) 2020-01-20
US20160362410A1 (en) 2016-12-15
US9932344B2 (en) 2018-04-03

Similar Documents

Publication Publication Date Title
US11566029B2 (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use
CA3075461C (en) 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as cdk inhibitors
JP7348665B2 (ja) 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体
WO2022263604A1 (en) Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use
EP4077330A1 (en) 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds and their therapeutic use
EP2476682A1 (en) 8-oxodihydropurine derivative
HK1231852A1 (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
HK1231852B (en) Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as cdk inhibitors and their therapeutic use
NZ763316B2 (en) 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as cdk inhibitors

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180911

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190312

R150 Certificate of patent or registration of utility model

Ref document number: 6498212

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250